Metabolism, Inflammation and Neurodegeneration: Natural Compounds as Therapeutic Agents
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: 25 March 2026 | Viewed by 6
Special Issue Editor
Interests: Alzheimer’s disease; brain energy metabolism; brain signaling; obesity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and other age-related disorders, are major global health challenges with profound social and economic impact. These conditions are closely linked to metabolic dysfunction and chronic inflammation, both of which accelerate neuronal damage and cognitive decline. Despite decades of research, the current therapeutic options remain largely symptomatic, highlighting the urgent need for novel, disease-modifying strategies.
Natural compounds offer a promising avenue for intervention, given their diverse bioactive properties, ability to target multiple molecular pathways, and favorable safety profiles. This Special Issue, titled “Metabolism, Inflammation and Neurodegeneration: Natural Compounds as Therapeutic Agents”, welcomes original research and reviews exploring the mechanistic roles, preclinical efficacy, and translational potential of natural molecules in mitigating the metabolic and inflammatory processes that drive neurodegeneration. By fostering multidisciplinary contributions, we aim to advance understanding and promote innovative approaches for the effective prevention and treatment of these devastating disorders.
Dr. Pedro Cisternas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative diseases
- natural compounds
- metabolic dysfunction
- neuroinflammation
- therapeutic strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
